Recursion Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary
06/05/2025 07:37
Recursion Pharmaceuticals Inc RXRX.OQ reported a quarterly adjusted loss of 50 cents per share for the quarter ended March 31, lower than the same quarter last year, when the company reported EPS of -39 cents. The mean expectation of five analysts for the quarter was for a loss of 52 cents per share. Wall Street expected results to range from -80 cents to -39 cents per share. Revenue rose 6.9% to $14.75 million from a year ago; analysts expected $18.12 million. Recursion Pharmaceuticals Inc's reported EPS for the quarter was a loss of 50 cents. The company reported a quarterly loss of $202.49 million. Recursion Pharmaceuticals Inc shares had fallen by 10.1% this quarter and lost 29.7% so far this year. FORECAST CHANGES The mean earnings estimate of analysts had risen by about 0.9% in the last three months. In the last 30 days, there have been no earnings estimate revisions by analysts covering the company. RECOMMENDATIONS The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy," 6 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "hold" Wall Street's median 12-month price target for Recursion Pharmaceuticals Inc is $8.00 This summary was machine generated from LSEG data May 6 at 06:36 a.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
| QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
| Mar. 31 2025 | -0.52 | -0.50 | Beat |
| Dec. 31 2024 | -0.43 | -0.53 | Missed |
| Sep. 30 2024 | -0.35 | -0.34 | Beat |
| Jun. 30 2024 | -0.40 | -0.40 | Met |
Recent news on Recursion Pharmaceuticals
See all newsBrief: Tempus And Recursion Extend Existing Data License Agreement And Enter New License Agreement For Recursion’S RNA Foundation Model
Brief: Recursion Pharmaceuticals Enters Amendment To Master Agreement With Tempus On Sept 15, 2026 - SEC Filing
Recursion Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Recursion Pharmaceuticals Q2 revenue misses estimates, cuts 2026 expense outlook
Brief: Recursion Pharmaceuticals Q2 Operating Revenue USD 7.303 Million Vs. IBES Estimate USD 11.9 Million